ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment OptionsJean‐Jacques Kiladjian, Christoph Klade, Francisca Ferrer‐Marín et al.|Blood|2024Cited by 0
Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia veraVeronika Buxhofer‐Ausch, Steffen Koschmieder, Krauth Maria-Theresa et al.|Blood|2025Cited by 0
Comparative analysis of ide-cel and cilta-cel in patients with Relapsed/Refractory multiple myeloma: A nationwide, retrospective, real-world analysis across AustriaIrene Straßl, Krauth Maria-Theresa, Alexander Nikoloudis et al.|Blood|2025Cited by 0